
NVIDIA (NVDA) offers strong multi-year revenue visibility, projected to generate up to $900 billion over the next five years through massive data center and power infrastructure deals. Investors can gain targeted exposure to AI hardware bottlenecks by buying optical networking leaders Lumentum (LITE) and Coherent (COHR), which are directly backed by multi-billion-dollar chipmaker investments. In healthcare, consider long-term positions in Moderna (MRNA) and Merck (MRK) as their AI-driven personalized melanoma cancer vaccine progresses toward potential regulatory approval by 2027. Increasing model vulnerabilities and complex autonomous agent exploits make AI cybersecurity a critical, high-growth sector for enterprise software allocations. Conversely, exercise caution with speculative humanoid robotics stocks like Unitree, where extreme post-IPO valuation spikes are outpacing real-world commercial adoption.